CEO Rachel McMinn buys 47,500 shares of NGNE at $20.40 amid 68.8% decline from 52-week high; stock down 53.9% in 30 days.
Rachel McMinn, CEO of Neurogene Inc., purchased 47,500 shares at $20.40 on 2024-11-22, bringing her total holdings to 1,297,859 shares. This transaction occurs against a backdrop of significant recent weakness: the stock is trading at $22.32, down 68.8% from its 52-week high of $71.53 and down 53.9% over the past 30 days. The company is unprofitable, with net income of $-20,217,000.00 for the most recent full fiscal year and $0.00 revenue in the latest quarter. The CEO's decision to acquire 47,500 additional shares during a period of severe stock underperformance warrants attention to whether this reflects confidence in an operational turnaround or whether it reflects other considerations not visible in public filings.